CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls

Upgrades Summary - Rothschild & Co Redburn upgraded Kenvue (KVUE) to Buy from Neutral with a price target of $22, down from $22.50, citing a more measured response from the Health and Human Services department regarding Tylenol usage concerns [2] - Rosenblatt upgraded Ciena (CIEN) to Buy from Neutral with a price target of $175, up from $127.50, following an innovation day that highlighted opportunities to network multiple AI data centers [2] - Citi upgraded Riot Platforms (RIOT) to Buy from Neutral with a price target of $24, up from $13.75, due to the company's transition to AI and high-performance computing [2] - JPMorgan also upgraded Riot Platforms to Overweight from Neutral with a price target of $19, up from $15 [2] - Goldman Sachs upgraded Ionis Pharmaceuticals (IONS) to Neutral from Sell with a price target of $65, up from $45, noting the company's transition to a commercial growth story [2] - RBC Capital upgraded Alkermes (ALKS) to Outperform from Sector Perform with a price target of $44, up from $42, based on positive analysis of potential narcolepsy type 2 treatment effects for alixorexton [2]